NY-CURIA/LAKEPHARMA
14.7.2021 15:02:06 CEST | Business Wire | Press release
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts, and Texas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005230/en/
Established in 2009 in the Bay Area, LakePharma applies its range of technology platforms to advance projects from discovery to development to manufacturing, namely cell-line development, bioexpression systems and viral vector production systems. Almost a quarter of its employees hold Ph.D.s, bringing expertise in all major biologics segments: mammalian, microbial, plasmid DNA, mRNA, monoclonal antibodies, and viral vector, including cell and gene therapy. LakePharma has contributed to the development of more than 200 therapeutic or diagnostic products and served more than 1,500 customers, including 22 of the top 25 global biopharmaceutical companies.
After the transaction close, the combined company will provide deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production. LakePharma’s six facilities and 235 employees will join with Curia’s 21 sites and more than 3,100 employees to offer clients an end-to-end partnership in drug discovery, formulation and process development as well as drug substance and drug product clinical and commercial manufacturing. Curia recently announced it has also signed a definitive agreement to acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California.
“LakePharma will expand our integrated approach to provide biotech and pharmaceutical companies with small and large molecule research, development and manufacturing solutions,” said Curia Chairman & CEO John Ratliff. “Funding and innovation in the biotech sector remains strong. Our combined capabilities will enable us to partner with our customers by seamlessly providing LakePharma’s multi-modality innovation and speed along with fill-finish solutions from Curia. Our agreements with LakePharma and Integrity Bio demonstrate our commitment to expanding and deepening our biologics capabilities to help our customers advance from curiosity to cure.”
Hua Tu, Ph.D., founder and CEO of LakePharma, said: “LakePharma is delighted to join the Curia family. Over the last 12 years, we have built a strong brand as 'The Biologics Company,' a talented and dedicated employee team, and a loyal and supportive client base. We are excited to join Curia’s global network, including commercial manufacturing capabilities, in delivering end-to-end integrated biologics solutions to our pharma and biotech clients.”
RBC Capital Markets, LLC is serving as exclusive financial adviser to Curia and Nelson Mullins Riley & Scarborough LLP is serving as Curia’s legal counsel. Goldman Sachs & Co. LLC is serving as financial adviser to LakePharma, and Fenwick & West LLP is serving as LakePharma’s legal counsel. The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com
.
About LakePharma
LakePharma is a U.S.-based biologics CRDMO with operations in California, Texas, and Massachusetts. This biotech company specializes in the production and evaluation of DNA vectors, viral vectors, cell lines, proteins, antibodies, mRNA and conjugates while providing integrated solutions bridging discovery, engineering, development, and GMP manufacturing. LakePharma has contributed to the development of 200+ therapeutic or diagnostic products and strives to develop hundreds more. Learn more at www.LakePharma.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005230/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sine kompetencer med tilføjelsen af Lukkap2.4.2026 16:31:00 CEST | Pressemeddelelse
Andersen Consulting tilføjer samarbejdspartneren Lukkap, et konsulenthus med fokus på oplevelsesdrevne kompetencer, der er tilpasset kundernes skiftende behov inden for transformation af medarbejdere, kunder og det digitale område. Lukkap, der blev stiftet i 2009 og har hovedsæde i Spanien, leverer integrerede løsninger, der hjælper organisationer med at transformere, hvordan de betjener kunder, engagerer medarbejdere og frigør værdi gennem adfærdsindsigt og dataanalyse. Virksomhedens tværfaglige tilgang spænder over nytænkning af kunderejsen, effektive programmer for medarbejderoplevelser, talent- og ledelsesudvikling, prædiktiv analyse samt omfattende outplacement- og transitionsydelser. Lukkap arbejder på tværs af sektorer — herunder sundhedsvæsen, medicinalindustri, forbrugsgoder, detailhandel, finans og bankvæsen — for at opbygge menneskecentrerede strategier, der skaber målbare forretningsresultater. "Ved at kombinere vores erfaringsdrevne metode med Andersen Consultings globale
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press release
Low AI fluency, uneven adoption, and marginal productivity gains are limiting enterprise-scale impact According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA® Fiber2.4.2026 15:00:00 CEST | Press release
Agreement with Texhong Advances Sustainable Fiber Applications The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang,
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press release
New identity reflects expanded vision to help CIOs “See Clearly. Spend Better.” Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly.
Lenovo 360 Framework Evolves with Simplified Tiers, Services Growth Pathways, and New Technical Community2.4.2026 15:00:00 CEST | Press release
New enhancements to Lenovo 360 make growth more intuitive, profitable, and collaborative for Lenovo partners Lenovo today announced new enhancements to its global channel framework, Lenovo 360, building on the success of its channel-centric model to further simplify and accelerate partner growth. Lenovo 360 has become the foundation for how Lenovo enables, connects with, and grows alongside its global partner ecosystem. These latest updates reflect Lenovo’s continued commitment to evolving the partner experience and creating more intuitive, scalable paths to growth. "The channel is central to how we do business,” said Pascal Bourguet, Chief Sales Strategy & Channels Officer at Lenovo. “It’s how we scale, how we innovate, and how we grow together. With these latest enhancements to Lenovo 360, we’re making it simpler, more predictable, and more rewarding for partners to build their business with us. From services-led growth to new technical communities and streamlined tiering, we’re focu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom